Genetico's RAS loss for 3 months of 2025 amounted to ₽20.9 million against a profit of ₽5 million in the previous year. Revenue increased 71.2% to ₽134.2 million vs. ₽78.4 million a year earlier.

Genetico's RAS loss for 2024 was ₽13.3 million, down 62.2% from ₽35.2 million in the previous year. Revenue rose 23.1% to ₽425.96 million against ₽346.1 million a year earlier.

Genetico has invested in biotech startup Retinostar, which develops advanced gene therapy drugs for the treatment of genetic and age-related eye diseases. Investment in the form of a convertible loan will amount to ₽20 million and will be used to validate ophthalmic disease models and conduct animal studies to select the most effective drug candidates and pr...

Genetico has received a patent for a panel developed by the company to search for somatic mutations in a tumor using the Onconetix next-generation sequencing method. Panel allows oncologists to obtain the most complete information about point mutations in the tumor to select an effective target therapy for cancer individually for each patient, taking into ac...